INTRODUCTION
The most deadly consequence of HIV infection, AIDS, can be successfully combated by combination antiretroviral therapy (cART). However, HIV enters the central nervous system (CNS) very early after infection [1] and continues to cause HIVassociated neurocognitive disorders (HANDs) in approximately 50% of HIV-infected individuals in the postcART era [2, 3] . cART-treated HIVinfected individuals are living longer and there is growing evidence that the ageing HIV-infected population may suffer from earlier onset of neurocognitive deficits [4] . In the periphery, HIV primarily replicates in CD4 þ T cells. However, cells of the macrophage lineage are the primary virus producers in the CNS. Thus, viral life cycle and immune responses are governed by unique mechanisms in brain. In this review, we highlight the most recent advances in understanding viral life cycle, innate immune responses and autophagy, one aspect of the innate immune response, in the CNS (Fig. 1) . These concepts are of critical importance for both eradication strategies and developing therapeutic targets to treat HAND.
HIV LIFE CYCLE IN THE CENTRAL NERVOUS SYSTEM
a complete understanding of viral entry into these cells and evolution of viral tropism during different stages of disease has important treatment consequences and may affect both peripheral and CNS disease progression.
Viruses were historically categorized on the basis of two somewhat related sets of criteria: the ability to infect T cells (T-tropic) or macrophages (M-tropic) or usage of the coreceptor CCR5 (R5) or CXCR4 (X4) for binding and fusion with target cells. Defining true macrophage tropism has been historically difficult due to the high level of inter-and intradonor macrophage variation, in addition to the fact that viral tropism/coreceptor usage is not always mutually exclusive [6] . Two recent studies used the recently developed Affinofile cell line [7] to titrate levels of CD4 and CCR5 and quantitatively evaluate CD4 and CCR5 requirements of both classically defined and patient-derived T-tropic (isolated from blood or lymph node) and M-tropic (isolated from brain or CSF) Env proteins. They found that M-tropic Env proteins are not CD4 independent, but rather are capable of infecting cells with very low CD4 surface densities [8,9 && ]. Furthermore, the conformation of brain-derived, M-tropic Env proteins had increased CD4-binding site exposure and alterations in the physical interactions with CCR5 compared with lymph node-derived, T-tropic isolates [9 && ].
Viral replication cells of macrophage lineage
Once inside the host cell, many factors can modify viral replication. Proinflammatory conditions enhance viral replication in most cell types. Chemokine (C-X-C motif) ligand 8 (CXCL8, interleukin-8) is produced by most cell types in the brain, enhances HIV replication in macrophages and
KEY POINTS
Macrophage tropic viruses require lower cell densities of CD4.
CTIP-2 promotes HIV latency in macrophages by multiple mechanisms.
HIV initiates inflammatory cascades in both infected and bystander cells; the interplay between the two is what dictates neurological disease.
Host factors such as age and genetics are important determinants of susceptibility to HAND.
The increased severity of HIV CNS disease in ageing patients is likely at least partly associated with agerelated declines in cellular autophagy.
Host Restriction
Factors (e.g., Mx1) T cells [10] , and is elevated in the cerebrospinal fluid (CSF) of patients with HIV-associated dementia compared with neurocognitively normal HIVinfected patients [11] . Mamik and Ghorpade [12 & ] extended these studies and found that CXCL8 increased formation of 2 long terminal repeat (2-LTR) circles, a marker of nuclear import of viral DNA or enhanced infectivity, in macrophages and primary microglia and that enhanced replication was dependent on nuclear factor of kappa light polypeptide gene enhancer in B-cells (NF-kB).
Virus Binding/Fusion
MicroRNAs (miRNAs) have also gained recent attention as modulators of HIV replication. miRNAs are small, approximately 22 nucleotide RNAs that inhibit translation of target mRNAs, usually via binding to the 3' UTR [13] . miRNAs can regulate the HIV life cycle by directly binding to and inhibiting translation of viral mRNA or by inhibiting translation of proteins involved in any stage the HIV life cycle. The number of publications implicating miRNAs in HIV regulation has exploded over the past several years [14] [15] [16] [17] . This review will highlight only the most recent publications that have relevance to viral replication in cells of the macrophage lineage. Using simian immunodeficiency virus (SIV) as a model, Sisk et al. [18 & ] recently identified four host miRNAs (miR-29a, miR-29b, miR-9 and miR-146a) that directly inhibit virus production and are produced in macrophages upon viral infection, likely via stimulation of interferon b (IFNb) or tissue necrosis factor alpha (TNFa). These miRNAs were also upregulated in human macrophages in response to IFNb or TNFa and two of the miRNAs (miR-29a and miR-29b) directly target HIV-1 transcripts [17,18 & ]. These findings support the growing body of literature highlighting the importance of miRNAs in not just the viral life cycle but also in the context of the immune response [19, 20] . Rather than directly binding to viral mRNA, Ma et al. [21] recently showed that miRNA-1236 represses translation of Vpr-binding protein (VprBP), thereby inhibiting HIV infection of monocytes, implicating miRNA-1236 as an endogenous inhibitor of viral replication. Differential expression of miRNA-1236 in monocytes (high) vs. macrophages (low) appears to partly explain the differential permissivity of these cells to viral replication [21] . Virus itself also usurps miRNA mechanisms for its own benefit. Casey Klockow et al. [22 & ] recently demonstrated that HIV enhances macrophage infection by targeting the miRNA processing protein Dicer for proteosomal degradation via Vpr. Overall, miRNA regulation of HIV replication is a rapidly growing field of investigation with many questions left to answer at all stages of viral replication, particularly in the CNS.
Viral latency in macrophages and microglia
In the current atmosphere of renewed hope for eradication, understanding latency in macrophages and microglia is of utmost importance. Although multiple mechanisms of latency have been identified [23], recent studies have further defined the role of COUP-TF interacting protein 2 (CTIP-2). CTIP-2 was previously shown to inhibit LTR transcription via histone deacetylase (HDAC) and histone methyltransferase (HMT) recruitment [24] . The same group has now found that CTIP-2 is part of a large, inactive P-TEFb complex on the HIV LTR in a microglial cell line and is recruited by HMGA1 [25 && ,26]. Furthermore, the P-TEFb-related transcriptional silencing mechanism is independent of CTIP-2 recruitment of HDAC and HMT [25 && ].
Infection of astrocytes
In contrast to macrophages, microglia and T cells, much less is known about HIV entry and replication in astrocytes, which do not express CD4. Gray et al.
[27] recently identified intracellular vesicles containing the tetraspanin-family protein CD81 as compartments containing HIV in astrocytes. Knocking down this protein decreased cell-associated virus, but the virus still associated with residual CD8 -containing vesicles, further supporting CD81-vesicles as important compartments for the viral life cycle in astrocytes.
Viral latency in astrocytes
Once infected, astrocytes only support very limited or restricted viral replication, although they may be capable of producing infectious virus in proinflammatory conditions [5] . Because astrocytes are the most numerous cell type in the brain, fully understanding mechanisms of viral replication and latency in these cells is critical. Narasipura et al. [28 & ] used primary human progenitor derived astrocytes and astrocytic cell lines to demonstrate that class I HDACs and HMTs, likely SU(VAR)3-9 in particular, are important in epigenetic silencing of HIV proviral DNA in astrocytes. SAHA, the class I HDAC inhibitor used for these experiments, is currently used in latency-reversing eradication strategies [29, 30] . Although the view of astrocytes as viral reservoirs is contentious, reactivation of HIV in these cells may have yet unforeseen consequences.
INNATE IMMUNITY IN THE CONTEXT OF HIV-ASSOCIATED NEUROLOGICAL DISEASE
The innate and adaptive immune systems play integral roles in minimizing host damage and clearing infection. Our understanding of HIV-induced dysfunction of the immune system is still evolving. For example, recent studies have revealed that pyroptosis, cell death specifically induced by inflammasome activity and mediated by caspase 1, is responsible for much of T cell death during infection. Monroe et al. [31] recently showed that loss of bystander, unactivated, CD4 þ T cells is largely due to pyroptosis and accompanies IL-1b secretion. This was demonstrated with both invitro and in-vivo data and pyroptosis may be able to be attenuated therapeutically. Doitsh et al. [32] identified an inducible protein that binds both dsDNA and ssDNA and induces CD4 þ T cell pyroptosis. Further, knockdown of this protein reduced CD4 þ T cell depletion. Although no specific role for pyroptosis in the development of HAND has been identified, it is a potential mechanism for cellular loss in the CNS.
A better understanding of the role of host immunity, particularly innate immunity, in HAND could mitigate both direct cytopathological effects and hyperactivation of adaptive immunity. In the last decade, immunologists have discovered and defined several mechanisms by which cells of the innate immune system respond to challenge, discoveries that drive our appreciation of innate immunity well beyond the convention of generic IFN response. Of particular interest are pattern recognition receptors (PRRs), which respond to specific pathogen-associated molecular patterns (PAMPs), and have made investigators take note of the complex responses the immune system can mount without adaptive immunity and memory. PRRs trigger a variety of signal transduction events that result in the expression of genes that have activity against pathogens (TNF, IFNa/b, chemokines, interleukins and so on). PRRs such as Tolllike receptors (TLRs), retinoic acid-inducible gene 1 (RIG-I) and RIG-I like receptors (RLRs) have been implicated in contributing to aberrant inflammation in the CNS through recognition of tissue damage molecular signals and aberrant responses to self [ ,37] ( Fig. 1) .
Recent developments in the literature have elaborated on and reaffirmed some of these previously described immunological processes. In the setting of acute SIV infection in macaques, IFNa transcripts were substantially lower in the brain vs. the periphery and changes specifically involved IFNa subtype 6 ] used human foetal microglia to reveal that stimulation with IFNa and HIV induced tetherin expression, a host restriction factor, which restricts viral budding. In addition, virus isolated from the brain of a HAND patient induced significantly less tetherin and Mx1 than virus isolated from toxoplasmosis encephalitis CSF. This indicates that neurovirulent HIV strains may evade tetherin and Mx1 via an undefined mechanism. These data were recapitulated using two feline immunodeficiency virus (FIV) strains, divergent in their Env proteins; after 10 days postinfection, tetherin and Mx1 were elevated in both. Further, analysis of an in-vivo FIV model of HIV neurovirulence demonstrated that while one strain induced TNFa and CD40, the other had a significant increase in tetherin and Mx1. These changes in tetherin/Mx1 were associated with IFN-related genes IRF3/IRF9 and not IFNa, TNFa or IL1-b. These studies support previous evidence that the brain is immunologically discrete, neurological inflammation may be dependent on viral strain and its complexities present unique challenges as therapeutic targets [34 && ,36 & ,37,40] ( Fig. 1 ). Recent studies have elucidated some functions of multinucleated giant cells (MNGCs), which are a common hallmark of HIV infection. Tarassishin et al. [41] recently demonstrated that MNGCs in the brain that were highly associated with IRF3 induction. Another group, Hornik et al. [42] , demonstrated that multinucleation could be triggered by TLR ligands, IFNb and proteins associated with Parkinson's disease (alpha-synuclein) and Alzheimer's disease (amyloid-beta) in a microglia cell line. This multinucleation occurred through abscission failure, not fusion or endocytosis. In addition, these MNGCs had increased phagocytic activity. These studies reinforce the idea that HIV neurological disease has mechanisms in common with other neurodegenerative disorders.
Specific microenvironments in the brain contain unique cells that exacerbate cytopathy in the brain. In a brain endothelial cell line, it was shown by Li et al. [43] that TLR ligands can induce IFNb/l expression in a dose-dependent manner. Application of supernatants from polyI:C activated endothelial cells to infected macrophages resulted in reduction of viral replication in a dose-dependent manner. This was accompanied by an increase in the IFN-associated genes ISG56, Mx1 and OAS-1.
Treatment of neutralizing antibody to IFNb and IL10-b receptor inhibited these effects. Geffin et al. [44] used neural epithelial cell (NEP) derived astrocyte/neuron cocultures to further investigate gene expression. Treatment with virus-containing medium upregulated 20 genes having to do with antigen presentation and immunity, including tetherin. The gene Apolipoprotein E (ApoE), which is linked with other neurocognitive diseases, was also investigated. Between NEP cultures with either E3/E3 or E3/E4 genotypes, E3/E4 cultures had significantly reduced expression patterns in eight of the previously identified 20 genes. These data demonstrate that cells other than classical inflammatory cells may play a critical role in inflammatory homeostasis in the brain. Further, host factors such as genetics may dictate dysregulation in these cell types of the brain (Fig. 1 ).
AUTOPHAGY AND HIV INFECTION OF THE CENTRAL NERVOUS SYSTEM
Autophagy is an important cellular mechanism that provides quality control of proteins and eliminates defective older intracellular organelles [45] . This is accomplished by the creation of autophagosomes, which consist of double membrane bodies that form within the cytoplasm and engulf cytoplasmic constituents such as subcellular organelles and microbial pathogens, including viruses, and target them for degradation by fusion with a lysosome (Fig. 1) . This process constitutes an important innate immune defense mechanism for host cells.
HIV appropriates autophagy for replication
As an intracellular parasite, HIV is dependent upon its ability to subvert host cell machinery for replication and dissemination, and to circumvent cellular processes that prevent its growth. Autophagy is one such intracellular process. HIV proteins can both promote and delay autophagy to facilitate different stages of viral replication in cells of monocyte/macrophage lineage. This suggests that these processes are also important in viral replication in the brain, wherein productive replication occurs almost exclusively in cells of macrophage lineage, which might modulate the pathogenesis of HAND. In fact, postmortem examination of brains from individuals with HIV encephalitis (HIVE) have more markers of autophagy than brains of HIV-infected individuals without encephalitis or uninfected individuals [46
&&
,47], suggesting a dysregulation of autophagy in HIVE [48] .
HIV replication in primary macrophages and monocytes is inhibited when autophagy-associated genes are silenced by RNAi [49] [50] [51] [52] , suggesting that HIV induces autophagy but blocks the late proteolytic stage. HIV assembly is thought to occur on endocytic membranes that intersect with recycling endosomes in macrophages [53, 54] , and Gag proteins colocalize with autophagosome membrane proteins suggesting that autophagy might be involved in Gag processing [55] . The HIV accessory protein Nef has been shown to induce autophagosome formation and enhance HIV replication [56] . In addition, during permissive infection, HIV prevents the fusion of autophagosomes with lysosomes [57 & ], further demonstrating how HIV may subvert autophagosomes to benefit the viral life cycle.
Autophagy as a host innate defense mechanism
On the contrary, there is much evidence supporting autophagy as an important player in the host's innate defense against HIV pathogenesis. In a recent study, PBMCs from HIV-infected long-term nonprogressors and elite controllers were shown to have significantly higher numbers of autophagic vesicles and higher levels of autophagic markers than normal progressors. In macrophages, virions were detectable in cells with moderate but not high levels of accumulated autophagosomes [52] . This suggests that autophagic vesicles limit viral pathogenesis in HIV-1 infection by targeting viral components for degradation [58 & ]. Deficits in autophagy have been identified in a number of ageing-associated diseases including Alzheimer's disease [59, 60] and Parkinson's disease [61, 62] . This association with ageing is important, given that the ageing population represents one of the fastest-growing populations of HIV-infected individuals [63] .
The association between ageing and autophagy dysfunction was supported by a recent study, in which differences in HIV viral load, CNS immune activation and expression of autophagy-related proteins were compared between HIV-infected individuals with encephalitis who were older than or younger than 50 years. Young HIVE patients displayed an increase in beclin-1, cathepsin-D and light chain 3, whereas these autophagy markers were reduced in aged HIVE cases compared with agematched HIV-positive donors [46 && ]. Similar alterations in autophagy markers were observed in aged gp120 transgenic (tg) mice [46 && ].
Autophagy as a therapeutic target for HIVassociated neurocognitive disorder
As autophagy works at the host cellular level to induce degradation of HIV, there has been substantial interest in identifying therapeutics that can manipulate this cellular process in combination with antiretroviral drugs to treat and potentially eradicate HIV. In addition, as autophagy is a naturally occurring host clearance mechanism, it is unlikely that viral resistance would develop. Rapamycin, a specific mTOR inhibitor and inducer of autophagy, inhibits HIV replication through both the downregulation of CCR5 [64] and the induction of autophagy [55] . It also inhibits HIV infection in human peripheral blood leukocytereconstituted severe combined immunodeficiency (SCID) mice and synergizes with a number of inhibitors of HIV entry [65] . However, rapamycin has immunosuppressive and other adverse effects that limit its potential usefulness in the treatment of HIV.
Vitamin D has well known antimicrobial effects, and low levels of 25-hydroxycholecalciferol (25D3) and/or the active metabolite 1a,25-dehydroxycholecalciferol (1,25D3) are associated with an increased risk of or severity of infection with HIV [64, 66] , thought to occur as a result of upregulation of autophagy [51, 67] . Vitamin D has also been implicated in the autophagic response to PAMPs by PRRs as TLR7/TLR8, stimulation activates a variety of antiviral effector functions including the induction of autophagy [50, 68] .
A recent study [69 && ] described production of a cell-permeable HIV Tat-beclin-1 fusion protein that binds to Nef and markedly inhibits HIV replication in primary human macrophages through the induction of autophagy. This peptide, which also restricts replication of a number of other viruses that cause encephalitis, holds therapeutic promise.
CONCLUSION Surprisingly, after 30 years of intensely studying the HIV life cycle, we still are discovering new facets of this process, particularly in cells of macrophage lineage, which emphasize the complexity of this virus's adaptations to host cell defenses. These new data emphasize the importance of innate defense mechanisms and basic homeostatic mechanisms for control of virus in the CNS, wherein adaptive immune mechanisms are inadequate. Manipulation of the process of autophagy is attractive as a potential therapeutic target, but this complex mechanism requires further investigation. 
